In a recent announcement, Beam Therapeutics Inc. revealed that Eli Lilly and Company (Lilly) will acquire certain rights from Beam’s collaboration and license agreement with Verve Therapeutics, Inc. This agreement includes Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, targeting PCSK9, ANGPTL3, and an undisclosed liver-mediated, cardiovascular target.
Under the terms of the agreement, Beam will receive an upfront payment of $200 million and a $50 million equity investment from Lilly. Additionally, Beam is eligible for up to $350 million in potential future development-stage payments, contingent on the completion of specific clinical, regulatory, and alliance milestones, resulting in a potential total deal consideration of up to $600 million.
Beam Therapeutics, a biotechnology company specializing in precision genetic medicines through base editing, views this collaboration as an opportunity to expand its portfolio of clinical and research-stage programs. Base editing is a proprietary technology that enables precise, predictable, and efficient single base changes in targeted genomic sequences, offering a potential therapeutic strategy for various diseases.
Lilly’s interest in this partnership is driven by the potential of single-course gene editing treatments for patients at risk of cardiovascular disease. The collaboration seeks to harness the full potential of Beam’s base editing platform and Verve’s cardiovascular disease programs to develop innovative therapeutic options.
This collaboration reflects Beam’s commitment to advancing genetic medicine and its goal of providing lifelong cures for serious diseases. However, investors should exercise caution, as the success of these endeavors depends on various factors, including regulatory approvals, clinical trial outcomes, and the availability of funding. Beam will continue to pursue its mission while closely monitoring potential risks and uncertainties associated with these developments.
https://www.fiercebiotech.com/biotech/beam-offloads-verve-rights-lilly-600m-and-more-deals-are-works
https://www.globenewswire.com/news-release/2023/10/31/2769940/0/en/Beam-Announces-Agreement-for-Lilly-to-Acquire-Beam-s-Opt-In-Rights-to-Verve-Therapeutics-Base-Editing-Programs-for-Cardiovascular-Disease.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
